Purpose: Ischemic stroke recurrence (ISR) is prevented by inhibiting platelet function. To investigate the impact of high on-treatment platelet reactivity (HTPR) assessed by thromboelastography (TEG) and its risk factors on ISR in individuals who have experienced acute ischemic stroke (AIS) receiving dual anti-platelet therapy (DAPT). Patients and Methods: At the end of follow-up, a total of 264 patients who met the criteria were enrolled in this cohort study. The primary endpoint event was a recurrence of ischemic stroke within 90 days of onset. Results: The ISR rate was 7.2% (19/264). The recurrence rate in the HTPR group was 15.1% (8/53), which was significantly higher than the 5.2% (11/211) in the non-HTPR group (p = 0.013), and the type 2 diabetes mellitus (T2DM) group (12.5%, 10/80) was also significantly higher compared to the non-T2DM group (4.9%, 9/184) (p = 0.028). T2DM was an isolated risk factor for HTPR (adjusted OR = 3.06, 95% CI 1.57– 5.98, P = 0.001). Kaplan-Meier plots showed that the cumulative risk (CR) of ISR was statistically different in the HTPR and T2DM groups compared to the non-HTPR group (log-rank P = 0.009) and the non-T2DM group (log-rank P = 0.026), respectively. The HTPR and T2DM groups had greater hazard ratios (HR) of ISR than the non-HTPR (adjusted HR = 2.78, 95% CI 1.06– 7.32, P = 0.038) and non-T2DM (adjusted HR = 2.64, 95% CI 1.01– 6.92, P = 0.049) groups. Conclusion: Both HTPR and T2DM are linked to ISR. Platelet Inhibition Rate (PIR) of TEG can early identify patients who are at high risk for having another ischemic stroke in patients undergoing DAPT, and this study may offer more evidence in favor of clinically personalized treatment and secondary prevention tactics.
Ciprofol (HSK3486), a novel intravenous anesthetic with a chemical structure similar to propofol, is not inferior to propofol in terms of its effectiveness. We compared the effects of ciprofol and propofol on dreams and emotional states in patients following painless gastroscopy. This was a single-center, randomized controlled trial. The primary outcome was the proportion of positive dreams during sedation. A total of 110 outpatients were included, with 55 in each group. The proportion of positive dreams among dreamers was significantly greater in the propofol group than in the ciprofol group (60.9% vs 20.0%; p = 0.020). Additionally, the propofol group exhibited significantly higher positive emotion scores compared to the ciprofol group (19 [15,25] vs 17 [12,21]; p = 0.021). No significant differences were observed in vital signs, BIS values, or satisfaction with the procedure between the two groups. As for the adverse drug reactions, the incidence of injection pain of propofol was significantly higher than that of ciprofol (12.7% vs 0%; p = 0.013). Compared to propofol, ciprofol demonstrated a weaker capacity to induce positive dreams and emotions during painless gastroscopy. However, this does not impact patient satisfaction with the procedure. www.chictr.org.cn; identifier: ChiCTR2400082655.